Table 2.
Basic description of the AF study cohorts.
| Data source | Patients (N)∗ | Mean age (±SD) at first OAC prescription | % female |
|---|---|---|---|
| Belgium LPD | 6546 | 74.5 (10.5) | 45 |
| France DA | 5053 | 73.6 (10.5) | 43 |
| Germany DA | 72,297 | 74.1 (10.1) | 47 |
| UK THIN | 52,720 | 74.1(10.5) | 44 |
| UK CPRD | 48,830 | 74.3 (10.5) | 44 |
| US LRxDx | 3,195,578 | 70.3 (10.5) | 45 |
| US PMTX | 193,118 | 63.1 (11.0) | 35 |
| US Marketscan CCAE | 97,220 | 56.2 (7.1) | 31 |
| US Marketscan MDCR | 170,971 | 78.0 (7.3) | 47 |
∗ Some patients could potentially contribute to more than one database, for example, THIN and CPRD databases in the UK. AF: atrial fibrillation; CCAE: Commercial Claims and Encounters; CPRD: Clinical Practice Research Datalink; DA: Disease Analyzer; IMRD: IQVIA Medical Research Data UK; LPD: Longitudinal Patient Database; LRxDx: Longitudinal Prescription Diagnosis database; MDCR: Medicare Supplemental and Coordination of Benefits; OAC: oral anticoagulant; PMTX: Pharmetrics; SD: standard deviation.